IP Library Granted Patent US 8,663,987
Granted Patent B2
US 8,663,987 · App. 12/994,761 · Granted Mar 4, 2014

Mesenchymal stem cells for the treatment of CNS diseases

Inventors: Avinoam Kadouri (Petach-Tikva, IL); Avihay Bar-Ilan (Tel-Aviv, IL); Eldad Melamed (Tel-Aviv, IL); Daniel Offen (Kfar HaRoe, IL); Ofer Sadan (Tel-Aviv, IL); Merav Bahat-Stromza (Haifa, IL)
Assignees: Ramot at Tel-Aviv University Ltd.; BrainStorm Cell Therapeutics Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,663,987
App. No.
12/994,761
Granted
Mar 4, 2014
Kind
B2
Abstract

An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.

Claims (6)

1. An isolated, non-genetically modified human cell differentiated from a bone marrow mesenchymal stem cell expressing at least one bone marrow derived mesenchymal stem cell marker, not secreting nerve growth factor (bNGF) and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of said BDNF is at least five times greater than a basal secretion of said BDNF in a non-differentiated, non-genetically modified mesenchymal stem cell, wherein said at least one bone marrow derived mesenchymal stem cell marker is selected from the group consisting of CD7, CD90 and CD105.

2. The isolated human cell of claim 1 , which takes up at least ten times more glutamate from its surroundings than said non-differentiated, non-genetically modified mesenchymal stem cell.

3. The isolated human cell of claim 1 , being star-shaped.

4. The isolated human cell of claim 1 , further expressing GFAP.

5. The isolated human cell of claim 1 , further expressing GDNF.

6. The isolated human cell of claim 1 , wherein said BDNF is secreted at a concentration of about 5782-8452 pg/10 6 cells.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2011
From: BRAINSTORM CELL THERAPEUTICS INC.
To: BRAINSTORM CELL THERAPEUTICS LTD.
Reel/Frame 027424/0597 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2011
From: MELAMED, ELDAD; OFFEN, DANIEL; SADAN, OFER; BAHAT-STROMZA, MERAV
To: RAMOT AT TEL-AVIV UNIVERSITY LTD.
Reel/Frame 026028/0277 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2010
From: KADOURI, AVINOAM; BAR-ILAN, AVIHAY
To: BRAINSTORM CELL THERAPEUTICS INC.
Reel/Frame 025424/0303 →
Continuity (2)
Provisional Application 61071970 · May 28, 2008
Related Publication 20120009673A1 · Jan 12, 2012